ClinicalTrials.gg
CompletedNCT03679143Updated Aug 14, 2019

The Safety, Tolerability and Pharmacokinetic Study of ZSP1273 in Healthy Volunteers.

A Phase 1 interventional study of ZSP1273 100 mg and Placebo 100 mg in Influenza, sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-14.

Sponsored by Guangdong Zhongsheng Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.

Enrollment
126th of 157
103 · median 360
Started
2018
with 8 others
Phase 1
25 of 173
2 open now
Registered
74th of 173
by date

Among the 173 studies in Influenza, Human with a site in China, this one is the 126th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2018, is one of 25 in phase 1, and was the 74th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Influenza, Human with a site in China, or all of them as a file.
02

Study summary

This is a single center,double-blind,randomized,parallel design, single and multiple dose trial to evaluate the pharmacokinetics(PK), safety and tolerability of ZSP1273,and the effect of food on ZSP1273 Pharmacokinetics.

Read the detailed description

The study will be divided in 3 parts :

Study Part I(Single Ascending Dosing, SAD) will be a single ascending dose to be run at a maximum of 6 dose levels. Subjects included in this part of the study will receive only one dose level to limit the exposure to ZSP1273. Four subjects are planned to be included in the first group while 10 subjects are enrolled in every following cohort.

Study Part II(Multiple Ascending Dosing, MAD) will start after completion of some Cohorts of Study Part I. Study Part II will be a multiple ascending dose to be run at a maximum of 3 dose levels. Subjects included in this part of the study will receive only one dose level. This part also enrolls 10 subjects in every cohort.

Study Part III(Food Effect study, FE) will consists of 2 periods,and subjects will receive a single dose ranged from 100-600mg on fasting and postprandial states respectively. There will be a 7-day wash out period between treatment periods.A total of 12 to 18 subjects will be included.

All the 3 parts will be run in healthy subjects.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects are required to meet the following criteria in order to be included in the trial:

  1. Signature of a dated Form (ICF) indicating that the subject has been informed of all the relevant aspects(including adverse events) of the trial prior to enrollment.
  2. Subjects must be willing and able to adhere to the visit schedule and protocol requirements and be available to complete the study.
  3. Subjects (including partners) must use reliable methods of during the study and until 6 months following the last dose of product.
  4. Males and female subjects between 18-50 years (Both inclusive).
  5. Body weight is no less than 50 kg in males and no less than 45 kg in females. (BMI) 18≤BMI≤28 kg/m2; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
  6. Physical condition and vital signs: Normal or abnormality has no clinical significance.

Exclusion criteria

Exclusion Criteria:

Eligible subjects must not meet any of the following exclusion criteria:

  1. Known and/or allergy to some drugs and food, especially for the composition that is similar to the investigative product;
  2. The average daily smoking are more than 5 cigarettes within 3 months prior to screening.
  3. Known history of drug or alcohol abuse.(defined as consumption of 14 units of alcohol per week: 1 unit = 285 ml of beer; or the equivalent of 25 ml of spirit, or 100 ml of wine )
  4. Subjects who donated blood or bleeding profusely (> 400 mL) in the 3 months preceding study screening.
  5. Dysphagia or any medical history in gastrointestinal that interferes with the absorption of drugs, include a history of frequent nausea or vomit causes by any etiology.
  6. History or presence of any disease or condition known to increase the risk of bleeding , eg. acute gastritis, duodenal ulcer, etc.
  7. Participant with any history of skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, or urticaria.
  8. Subjects with recent significant change in diet or exercise.
  9. Participated in another clinical research study and received any products within 3 months prior to dosing.
  10. Concomitant therapy with any drugs with known hepatic enzyme-inducing or inhibiting agents prior to screening or during the study, including strong inhibitory agents and inducers that affect metabolic enzymes (see appendix 6 for specific drug information).
  11. Use of any prescription or over-the-counter (OTC) medications, vitamins and herbal or dietary supplements within 14 days prior to screening.
  12. History of having any special food (including dragon fruit, mango, grapefruit, etc.), strenuous exercises, or other factors may interfere with the absorption, distribution, metabolism, or excretion of drug within 14 days prior to screening.
  13. Inability to consume the food provided in the study ( a high fat, high calorie meal includes two eggs , a piece of butter bacon toast, a box of fried potatoes, and a glass of whole milk).This requirement only applies to subjects under fed condition.
  14. Presence of clinically significant abnormalities in or >470ms in males, or QTcB>480ms in females.
  15. Pregnancy or breastfeeding at screening and during the study. All female subjects of must have a negative urine pregnancy test at screening and during the trial.
  16. Any clinically significant abnormality upon physical examination or presence of a clinically significant gastrointestinal, renal, hepatic, neurologic, hematic, endocrine, neoplastic, pulmonary, immune, psychiatric or cardiovascular and cerebrovascular disorder(s)(but not limited to above disorders) in the 6 months preceding study screening.
  17. Positive surface antigen, virus antibody, (HIV) or treponema pallidum antibodies at screening.
  18. Any acute illness or concomitant medication from screening to first dosing.
  19. Have chocolate, any food or beverage that contains caffeine or xanthine within 24 hours prior to dosing.
  20. Positive for urine drug screening or history of substance and drug abuse for a period of 5 consecutive years before screening.
  21. Subjects who may not complete the study for other reasons or should not be included in the study in the opinion of the investigator.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    ZSP1273(single dose)-100 mg(Cohort 1)

    ZSP1273 100 mg /Placebo

    Drug: ZSP1273 100 mg · Drug: Placebo 100 mg

  • Experimental
    ZSP1273(single dose)-200 mg(Cohort 2)

    ZSP1273 200mg/Placebo Enrollment into Cohort 2 will begin upon assurance of tolerance for Cohort 1.

    Drug: ZSP1273 200 mg · Drug: Placebo 200 mg

  • Experimental
    ZSP1273(single dose)-400 mg(Cohort 3)

    ZSP1273 400mg/Placebo Enrollment into Cohort 3 will begin upon assurance of tolerance for Cohort 2.

    Drug: ZSP1273 400 mg · Drug: Placebo 400 mg

  • Experimental
    ZSP1273(single dose)-600 mg(Cohort 4)

    ZSP1273 600 mg/Placebo Enrollment into Cohort 4 will begin upon assurance of tolerance for Cohort 3.

    Drug: ZSP1273 600 mg · Drug: Placebo 600 mg

  • Experimental
    ZSP1273(single dose)-900 mg(Cohort 5)

    Drug:ZSP1273 900 mg/Placebo 900mg; Enrollment into Cohort 5 will begin upon assurance of tolerance for Cohort 4.

    Drug: ZSP1273 900 mg · Drug: Placebo 900 mg

  • Experimental
    ZSP1273(single dose)-1200 mg(Cohort 6)

    ZSP1273 1200 mg/Placebo Enrollment into Cohort 6 will begin upon assurance of tolerance for Cohort 5.

    Drug: ZSP1273 1200 mg · Drug: Placebo 1200 mg

  • Experimental
    ZSP1273(Food Effect)-Cohort 7

    Drug:ZSP1273 /Placebo; Period 1 (Day1 to Day5): Subjects receive ZSP1273/Placebo under the fasting or fed condition ,respectively on Day1. Period 2 (Day 8 to Day12): Subjects receive ZSP1273/Placebo under the fed or fasting condition, respectively on Day 8.

    Drug: ZSP1273 · Drug: Placebo

  • Experimental
    ZSP1273(multiple doses)-Low Dose(Cohort 8)

    while fasted or fed according to the results of Cohort FE ZSP1273 /Placebo for 5 Days.

    Drug: ZSP1273 Low Dose · Drug: Placebo

  • Experimental
    ZSP1273(multiple doses)-Median Dose(Cohort 9)

    while fasted or fed according to the results of Cohort FE ZSP1273/Placebo for 5 Days.

    Drug: ZSP1273 Median Dose · Drug: Placebo

  • Experimental
    ZSP1273(multiple doses)-High Dose(Cohort 10)

    while fasted or fed according to the results of Cohort FE ZSP1273/Placebo for 5 Days.

    Drug: ZSP1273 High Dose · Drug: Placebo

Interventions

  • ZSP1273 tablet administered orally once daily under fasted condition

  • DrugPlacebo 100 mg

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state.

  • ZSP1273 tablets administered orally once daily under fasted condition

  • DrugPlacebo 200 mg

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 tablets administered orally once daily in the fasting state

  • DrugPlacebo 400 mg

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

  • ZSP1273 tablets administered orally once daily under fasted condition

  • DrugPlacebo 600 mg

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 tablets administered orally once daily in the fasting state

  • DrugPlacebo 900 mg

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted condition

  • ZSP1273 tablets administered orally once daily in the fasting state

  • DrugPlacebo 1200 mg

    Participants will receive placebo matching to ZSP1273 orally once daily in the fasting state

  • ZSP1273 tablets administered orally once daily under fasted or fed condition

  • DrugPlacebo

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition

  • ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.

  • DrugPlacebo

    Participants will receive placebo matching to ZSP1273 orally once daily under fasted or fed condition for 5 Days.

  • ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • DrugPlacebo

    Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

  • DrugPlacebo

    Participants will receive placebo matching to ZSP1273 orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.

06

What researchers measure

Primary outcomes

  1. Number and severity of treatment-emergent adverse events (TEAEs) and Serious Adverse Events(SAE)

    Number of participants with TEAEs as assessed by CTCAE v5.0.

    Time frame: At day 5, 9, 12 days post first dosing for SAD, MAD, FE part respectively

Secondary outcomes

  1. Tmax

    The time after dosing when Cmax occurs (Tmax)

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  2. Cmax

    Maximum concentration (Cmax)

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  3. t1/2z

    t1/2z is defined as the time to decline half of the drug concentration in plasma.

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  4. AUCinf(AUC0-∞)

    Area under the curve extrapolated until time is infinity (AUCinf)

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  5. AUClast(AUC0-t)

    AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  6. CL/F

    CL/F is defined as the ratio of total clearance(Cl) to bioavailability(F).

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  7. λz

    λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  8. CLr

    CLr is defined as how many milliliters of plasma in which some substance can be completely eliminated in the unit time (per minute) of two kidneys.

    Time frame: UP to 5, 9, 12 days for SAD, MAD, FE part respectively

  9. Food Effect PK Parameter: Fe0-t

    Fe0-t is defined as the cumulative excretion rate of the drug in urine and feces.

    Time frame: UP to 12 days

  10. Food Effect PK Parameter: Ae

    Ae is defined as the amount of unchanged drug excreted in urine or faeces after administration.

    Time frame: UP to 12 days

  11. Multiple-dose plasma PK parameter: Rac of ZSP1273 at steady state

    Rac (Accumulation Index) is defined as the ratio between AUC0-XX in Day XX and AUC0-XX in Day1

    Time frame: Up to 9 days

  12. Multiple-dose plasma PK parameter: DF of ZSP1273 at steady state

    DF is defined as the percentage of fluctuation in steady state is 100 \* (Cmax, ss - Cmin, ss)/Cavg, ss.

    Time frame: Up to 9 days

  13. Multiple-dose plasma PK parameter: Cmin of ZSP1273 at steady state

    Cmin is defined as the minimum observed concentration of drug in plasma at steady state.

    Time frame: Up to 9 days

07

Study locations

1 site
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
08

References and documents

Publications

  • Hu Y, Li H, Wu M, Zhang H, Ding Y, Peng Y, Li X, Yu Z. Single and multiple dose pharmacokinetics and safety of ZSP1273, an RNA polymerase PB2 protein inhibitor of the influenza A virus: a phase 1 double-blind study in healthy subjects. Expert Opin Investig Drugs. 2021 Nov;30(11):1159-1167. doi: 10.1080/13543784.2021.1994944. Epub 2021 Nov 1. PubMed 34654349 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Mar 2019, 5 months.

Of 94 industry-sponsored phase 1 interventional studies under Influenza, Human, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 5 months is below that.

Counting every sponsor, half of 148 studies reached it within 11 months; a quarter within 4 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2018
First posted
Sep 20, 2018
StartActual
Sep 20, 2018
Primary completionActual
Mar 19, 2019
CompletionActual
Apr 26, 2019
Last update
Aug 14, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03679143
Responsible party
Sponsor
First posted
Sep 20, 2018
Start date
Sep 20, 2018
Primary completion
Mar 19, 2019
Completion
Apr 26, 2019
Last update
Aug 14, 2019

Study contacts

Yanhua Ding, MD
principal investigator · The First Hospital of Jilin University
Shucheng Hua, MD
principal investigator · The First Hospital of Jilin University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ZSP1273

Start the discussion